Orion Corporation (Finnish company)

This article is about the pharmaceutical company. For other companies named Orion, see Orion (disambiguation).

Orion Corporation
Native name
Orion Oyj
Company typeJulkinen osakeyhtiö
Nasdaq Helsinki: ORNAV, ORNBV
IndustryPharmaceutical industry
Founded21 September 1917; 107 years ago (1917-09-21)
HeadquartersEspoo, Finland
Key people
Liisa Hurme (President and CEO), Mikael Silvennoinen (Chairman)
ProductsPharmaceuticals and active pharmaceutical ingredients
RevenueDecrease €1.041 billion (2021)
Decrease €243.3 million (2021)
Decrease €193.8 million (2021)
Total assetsDecrease €1.114 billion (2021)
Total equityIncrease €747.9 million (2021)
Number of employees
Increase 3,364 (2021)
Websitewww.orion.fi/en
Footnotes / references
[1]

Orion Corporation (Finnish: Orion Oyj),[2][3] founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.[4]

Orion's class A and B shares are listed on the Helsinki Stock Exchange.

History

[edit]

Orion was founded on September 21, 1917 by pharmacists Onni Turpeinen, Eemil Tuurala and Wikki Valkama. Before founding Orion, they worked in a pharmaceutical-chemical factory called Medica. The first premises of the new company were found in a courtyard building in Helsinki's Kruununhaka, Mariankatu 24, i.e. Asunto Oy Mars star. Among the first products of the apothecary were Ballistol gun oil and dulcine.[5] Pediatrician Arvo Ylppö played a significant role starting in the 1920s.[6]

Orion's diagnostics business was previously concentrated in the Orion Diagnostica profit unit, which was sold to a private equity investor in April 2018.[7] The diagnostics business included the development, manufacture and marketing of diagnostic tests and hygiene tests. Orion Diagnostica changed its name in November 2019 and is now Aidian.[8]

Notable products

[edit]

The following are Orion's top-selling product lines as of March 2021.[9]

Trade name Generic name Indication
Stalevo,Comtess/ Comtan Entacapone Parkinson's disease
Easyhaler multi-dose dry-powder inhaler for asthma. asthma, COPD
Simdax Levosimendan acute heart failure
dexdor dexmedetomidine intensive care sedative
Dexdomitor dexmedetomidine animal sedative
Domitor medetomidine animal sedative
Domosedan detomidine animal sedative
Antisedan atipamezole reversing agent
Nubeqa Darolutamide non-metastatic castration-resistant prostate cancer
Solomet Methylprednisolone inflammation
Divina series Estradiol valerate and Medroxyprogesterone acetate hormone replacement against menopausal symptoms
Fareston Toremifene Selective estrogen receptor modulator
Burana ibuprofen inflammatory pain
Marevan warfarin anticoagulant

References

[edit]
  1. ^ https://www.orion.fi/globalassets/documents/orion-group/investors/interim-reports/2021/en_orion_fy_2021.pdf [bare URL PDF]
  2. ^ "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.
  3. ^ "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.
  4. ^ "About Orion".
  5. ^ "Orionin virstanpylväitä 1910-luvulla". www.orion.fi. Retrieved 25 July 2022.
  6. ^ "Orionin vahva mies | Arvo Ylppö". www.ylppo.fi. Retrieved 25 July 2022.
  7. ^ Moran, Mark (18 May 2018). "AJP Board Member Responds to NYT Story On Antidepressant Withdrawal". Psychiatric News. 53 (10). doi:10.1176/appi.pn.2018.5b14. ISSN 0033-2704.
  8. ^ "Orion Diagnostica on nyt Aidian". Aidian (in Finnish). Retrieved 25 July 2022.
  9. ^ https://www.orion.fi/globalassets/documents/orion-group/investors/interim-reports/2021/en_orion_q1_2021_slides.pdf [bare URL PDF]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Orion_Corporation_(Finnish_company)&oldid=1256159414"